ClinConnect ClinConnect Logo
Search / Trial NCT00305162

A Clinical Trial to Demonstrate the Efficacy of Cangrelor

Launched by THE MEDICINES COMPANY · Mar 20, 2006

Trial Information

Current as of May 23, 2025

Terminated

Keywords

Acute Coronary Syndrome (Acs) Percutaneous Coronary Intervention (Pci) Non St Segment Elevation Myocardial Infarction (Nstemi) St Segment Elevation Myocardial Infarction (Stemi)

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • INCLUSION CRITERIA
  • To be included in this study, subjects must meet the following criteria:
  • Angiography demonstrating atherosclerosis amenable to treatment by percutaneous coronary intervention (PCI) with or without stent implantation and diagnosis of Acute Coronary Syndrome (ACS) by elevated cardiac markers or ischemic chest discomfort w/electrocardiogram changes + age \> 65 or diabetes or ST-elevation MI.
  • EXCLUSION CRITERIA
  • Subjects will be excluded from the study if they present with any of the following:
  • 1. Not a candidate for PCI
  • 2. Increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke, tumor, cerebral arteriovenous malformation, or intracranial aneurysm; recent (\<1 month) trauma or major surgery (including by-pass surgery); currently receiving warfarin, active bleeding
  • 3. Impaired hemostasis: known International Normalized Ratio (INR) \>1.5 at screening; past or present bleeding disorder (including congenital bleeding disorders such as von Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained clinically significant bleeding disorders), thrombocytopenia (platelet count \<100,000/µL), or history of thrombocytopenia or neutropenia associated with clopidogrel
  • 4. Severe hypertension not adequately controlled by antihypertensive therapy at the time of randomization
  • 5. Receipt of fibrinolytic therapy in the 12 hours preceding randomization
  • 6. Receipt of clopidogrel dose exceeding maintenance dose (ie, \>75 mg) at any time in the 5 days preceding randomization
  • 7. Inability to swallow study capsules
  • 8. Glycoprotein IIb/IIIa (GPI) Inhibitor usage within the previous 12 hours \[applicable to unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) patients\]
  • Subjects excluded for any of the above reasons may be re-screened for participation at any time if the exclusion characteristic has changed.

About The Medicines Company

The Medicines Company, a global pharmaceutical organization, is dedicated to advancing innovative therapeutic solutions to address urgent medical needs. Focused on developing and commercializing novel medicines, the company specializes in critical care and cardiovascular therapies. With a commitment to rigorous scientific research and clinical excellence, The Medicines Company aims to improve patient outcomes through its robust pipeline of products and collaborative partnerships within the healthcare community. Through its dedication to innovation and patient-centric approaches, the company strives to enhance the quality of life for patients worldwide.

Locations

Philadelphia, Pennsylvania, United States

Patients applied

0 patients applied

Trial Officials

Deepak L. Bhatt, MD

Principal Investigator

The Cleveland Clinic

Robert A. Harrington, MD

Principal Investigator

Duke University Medical Center and Duke Clinical Research Institute

Simona Skerjanec, PharmD

Study Director

The Medicines Company

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials